
David Lanfear
Vice President of Research and Chief Scientific Officer · Henry Ford Health
Credentials: · · · ·
History
Research
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
New England Journal of Medicine · 2021 · 487 citations
Circulation · 2019 · 342 citations
Journal of Allergy and Clinical Immunology · 2011 · 284 citations

47 papers

26 papers

22 papers

17 papers

16 papers

14 papers

14 papers

13 papers
Grants
- 2026–2031
MUlti-Dimensional taiLored Telehealth Intervention for HFpEF (MULTI-HFpEF)
National Institute on Aging · R01
PI · $799.9K · Ut Southwestern Medical Center
- 2024–2027
Development of Polygenic Scores for Medication Response in Diverse Populations
National Heart, Lung, and Blood Institute · R21
Contact PI · $449.4K · Henry Ford Health + Michigan State University Health Sciences
- 2021–2027
National Institute on Minority Health and Health Disparities · P50
Project lead · $1.9M · Wayne State University
- 2017–2022
Plasma Metabolomics and Myocardial Energetics in Heart Failure
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.1M · Henry Ford Health System
Clinical trials
- 2026–2027
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Principal investigator · Recruiting
David Lanfear
- 2023–2027
- 2020–2022
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
Principal investigator · Completed · Phase 1
AstraZeneca
- 2026–2027
A Study of LY3971297 in Participants With Heart Failure
Site PI · Recruiting · Phase 1
Eli Lilly and Company



